{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:17:49Z","timestamp":1788247069264,"version":"build-2803163510"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuromol Med"],"DOI":"10.1007\/s12017-026-08948-3","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:57:24Z","timestamp":1788202644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rebalancing \u03b1-Synuclein Clearance: Novel Therapeutic Frontiers in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"28","author":[{"given":"Maryam","family":"Jabeen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-8644","authenticated-orcid":false,"given":"Huma","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tehreem","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab Ahmad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"8948_CR96","doi-asserted-by":"publisher","unstructured":"Abe, T. (2024). Lysosomal stress drives the release of pathogenic \u03b1-synuclein from macrophage lineage cells via the LRRK2-Rab10 pathway. Iscience, 27(2), 108893. https:\/\/doi.org\/10.1016\/j.isci.2024.108893","DOI":"10.1016\/j.isci.2024.108893"},{"issue":"5","key":"8948_CR41","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/pharmaceutics16050609","volume":"16","author":"A Abioye","year":"2024","unstructured":"Abioye, A., et al. (2024). Nonintuitive Immunogenicity and Plasticity of Alpha-Synuclein Conformers: A Paradigm for Smart Delivery of Neuro-Immunotherapeutics. Pharmaceutics, 16(5), 609.","journal-title":"Pharmaceutics"},{"issue":"1","key":"8948_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1471-4159.2006.03731.x","volume":"97","author":"KJ Ahn","year":"2006","unstructured":"Ahn, K. J., et al. (2006). Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. Journal Of Neurochemistry, 97(1), 265\u2013279.","journal-title":"Journal Of Neurochemistry"},{"issue":"1","key":"8948_CR88","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","volume":"272","author":"M Alfaidi","year":"2024","unstructured":"Alfaidi, M., Barker, R. A., & Kuan, W. L. (2024). An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease. Journal Of Neurology, 272(1), 21.","journal-title":"Journal Of Neurology"},{"issue":"3","key":"8948_CR110","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3390\/biom15030327","volume":"15","author":"AA Alhowyan","year":"2025","unstructured":"Alhowyan, A. A., & Harisa, G. I. (2025). From Molecular Therapies to Lysosomal Transplantation and Targeted Drug Strategies: Present Applications, Limitations, and Future Prospects of Lysosomal Medications. Biomolecules, 15(3), 327.","journal-title":"Biomolecules"},{"issue":"3","key":"8948_CR108","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2217\/nnm-2020-0372","volume":"16","author":"E Alimohammadi","year":"2021","unstructured":"Alimohammadi, E., et al. (2021). Potential treatment of Parkinson\u2019s disease using new-generation carbon nanotubes: A biomolecular in silico study. Nanomedicine: The Official Journal Of The American Academy Of Nanomedicine, 16(3), 189\u2013204.","journal-title":"Nanomedicine: The Official Journal Of The American Academy Of Nanomedicine"},{"key":"8948_CR57","doi-asserted-by":"publisher","first-page":"103173","DOI":"10.1016\/j.conb.2026.103173","volume":"98","author":"JK Andersen","year":"2026","unstructured":"Andersen, J. K. (2026). Implications of cellular senescence in Parkinson\u2019s disease: Recent developments and future directions. Current Opinion in Neurobiology, 98, 103173.","journal-title":"Current Opinion in Neurobiology"},{"issue":"4","key":"8948_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/mds.28941","volume":"37","author":"L Barba","year":"2022","unstructured":"Barba, L., et al. (2022). Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders, 37(4), 669\u2013683.","journal-title":"Movement Disorders"},{"issue":"3","key":"8948_CR70","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/med.22091","volume":"45","author":"G Bellini","year":"2025","unstructured":"Bellini, G., et al. (2025). \u03b1-Synuclein in Parkinson\u2019s Disease: From Bench to Bedside. Medicinal Research Reviews, 45(3), 909\u2013946.","journal-title":"Medicinal Research Reviews"},{"key":"8948_CR15","doi-asserted-by":"crossref","unstructured":"Brice\u00f1o, A. (2026). Aminochrome-Induced Disruption of Autophagosome-Lysosome Fusion: Implications for Protein Aggregation in Parkinson\u2019s Disease.","DOI":"10.20944\/preprints202602.1849.v1"},{"issue":"1","key":"8948_CR103","doi-asserted-by":"publisher","first-page":"20220359","DOI":"10.1515\/tnsci-2022-0359","volume":"15","author":"H Cai","year":"2024","unstructured":"Cai, H., et al. (2024). Lipid-based nanoparticles for drug delivery in Parkinson\u2019s disease. Translational Neuroscience, 15(1), 20220359.","journal-title":"Translational Neuroscience"},{"issue":"3","key":"8948_CR55","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi, P., et al. (2023). Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death & Disease, 14(3), 176.","journal-title":"Cell Death & Disease"},{"issue":"1","key":"8948_CR97","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41531-024-00760-9","volume":"10","author":"B Cao","year":"2024","unstructured":"Cao, B., et al. (2024). PDCD4 triggers \u03b1-synuclein accumulation and motor deficits via co-suppressing TFE3 and TFEB translation in a model of Parkinson\u2019s disease. npj Parkinson\u2019s Disease, 10(1), 146.","journal-title":"npj Parkinson\u2019s Disease"},{"key":"8948_CR44","unstructured":"Caredio, D. (2025). Neural and Extraneural Alterations Throughout Disease Progression in Prion Diseases. University of Zurich."},{"issue":"1","key":"8948_CR90","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/JPD-202221","volume":"11","author":"AM Castonguay","year":"2021","unstructured":"Castonguay, A. M., Gravel, C., & L\u00e9vesque, M. (2021). Treating Parkinson\u2019s disease with antibodies: Previous studies and future directions. Journal of Parkinson\u2019s Disease, 11(1), 71\u201392.","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"23","key":"8948_CR45","doi-asserted-by":"publisher","first-page":"13049","DOI":"10.3390\/ijms252313049","volume":"25","author":"O Cehlar","year":"2024","unstructured":"Cehlar, O., et al. (2024). Structures of oligomeric states of tau protein, amyloid-\u03b2, \u03b1-synuclein and prion protein implicated in Alzheimer\u2019s disease, Parkinson\u2019s disease and prionopathies. International Journal of Molecular Sciences, 25(23), 13049.","journal-title":"International Journal of Molecular Sciences"},{"key":"8948_CR3","doi-asserted-by":"publisher","first-page":"719590","DOI":"10.3389\/fcell.2021.719590","volume":"9","author":"L Chen","year":"2021","unstructured":"Chen, L., & Kashina, A. (2021). Post-translational modifications of the protein termini. Frontiers in cell and developmental biology, 9, 719590.","journal-title":"Frontiers in cell and developmental biology"},{"key":"8948_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cca.2022.02.006","volume":"529","author":"R Chen","year":"2022","unstructured":"Chen, R., Gu, X., & Wang, X. (2022). \u03b1-Synuclein in Parkinson\u2019s disease and advances in detection. Clinica chimica acta, 529, 76\u201386.","journal-title":"Clinica chimica acta"},{"issue":"4","key":"8948_CR106","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.3390\/ijms25042360","volume":"25","author":"MC Chiang","year":"2024","unstructured":"Chiang, M. C., et al. (2024). Gold nanoparticles in neurological diseases: A review of neuroprotection. International journal of molecular sciences, 25(4), 2360.","journal-title":"International journal of molecular sciences"},{"issue":"5","key":"8948_CR50","doi-asserted-by":"publisher","first-page":"eady6978","DOI":"10.1126\/sciadv.ady6978","volume":"12","author":"SJ Choi","year":"2026","unstructured":"Choi, S. J., et al. (2026). \u03b1-Synuclein expression is required for somatodendritic dopamine release and immediate early gene induction. Science Advances, 12(5), eady6978.","journal-title":"Science Advances"},{"issue":"1","key":"8948_CR71","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00018-024-05419-5","volume":"81","author":"L Dai","year":"2024","unstructured":"Dai, L., et al. (2024). Lysosomal dysfunction in \u03b1-synuclein pathology: molecular mechanisms and therapeutic strategies. Cellular And Molecular Life Sciences, 81(1), 382.","journal-title":"Cellular And Molecular Life Sciences"},{"key":"8948_CR105","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bioactmat.2024.04.005","volume":"38","author":"W Dai","year":"2024","unstructured":"Dai, W., et al. (2024). Brain delivery of fibronectin through bioactive phosphorous dendrimers for Parkinson\u2019s disease treatment via cooperative modulation of microglia. Bioactive Materials, 38, 45\u201354.","journal-title":"Bioactive Materials"},{"issue":"1","key":"8948_CR95","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s00018-024-05419-5","volume":"81","author":"L Dai","year":"2024","unstructured":"Dai, L., et al. (2024). Lysosomal dysfunction in \u03b1-synuclein pathology: Molecular mechanisms and therapeutic strategies. Cellular and Molecular Life Sciences, 81(1), 382.","journal-title":"Cellular and Molecular Life Sciences"},{"key":"8948_CR92","doi-asserted-by":"publisher","first-page":"e98649","DOI":"10.7554\/eLife.98649","volume":"13","author":"Y Date","year":"2024","unstructured":"Date, Y., et al. (2024). Novel autophagy inducers by accelerating lysosomal clustering against Parkinson\u2019s disease. Elife, 13, e98649.","journal-title":"Elife"},{"key":"8948_CR52","doi-asserted-by":"crossref","unstructured":"Deyell, J. S. (2023). The Interplay between \u03b1-Synuclein and Microglia in \u03b1-Synucleinopathies. International Journal Of Molecular Sciences, 24(3) , 2477.","DOI":"10.3390\/ijms24032477"},{"issue":"1","key":"8948_CR123","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41531-025-01154-1","volume":"11","author":"NT Dhruv","year":"2025","unstructured":"Dhruv, N. T., et al. (2025). Mapping the developmental path for Parkinson\u2019s disease therapeutics. npj Parkinson\u2019s Disease, 11(1), 313.","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"15","key":"8948_CR79","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","volume":"64","author":"G Dong","year":"2021","unstructured":"Dong, G., et al. (2021). Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery. Journal Of Medicinal Chemistry, 64(15), 10606\u201310620.","journal-title":"Journal Of Medicinal Chemistry"},{"key":"8948_CR58","doi-asserted-by":"publisher","first-page":"645996","DOI":"10.3389\/fnagi.2021.645996","volume":"13","author":"T Du","year":"2021","unstructured":"Du, T., et al. (2021). Biomarkers and the Role of \u03b1-Synuclein in Parkinson\u2019s Disease. Frontiers in aging neuroscience, 13, 645996.","journal-title":"Frontiers in aging neuroscience"},{"issue":"3","key":"8948_CR67","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3390\/cimb48030254","volume":"48","author":"C Duarte","year":"2026","unstructured":"Duarte, C., et al. (2026). Parkinson\u2019s Disease: From Metabolism to Genetics\u2014A Comprehensive Review. Current Issues in Molecular Biology, 48(3), 254.","journal-title":"Current Issues in Molecular Biology"},{"issue":"10","key":"8948_CR102","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.2174\/0118715273283338240104112106","volume":"23","author":"J Fatima","year":"2024","unstructured":"Fatima, J., & Siddique, Y. H. (2024). Application of nanocomposites and nanoparticles in treating neurodegenerative disorders. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders, 23(10), 1217\u20131233.","journal-title":"CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders"},{"issue":"1","key":"8948_CR82","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1038\/ncomms6857","volume":"5","author":"L Fonseca-Ornelas","year":"2014","unstructured":"Fonseca-Ornelas, L., et al. (2014). Small molecule-mediated stabilization of vesicle-associated helical \u03b1-synuclein inhibits pathogenic misfolding and aggregation. Nature Communications, 5(1), 5857.","journal-title":"Nature Communications"},{"issue":"23","key":"8948_CR19","doi-asserted-by":"publisher","first-page":"12983","DOI":"10.3390\/ijms222312983","volume":"22","author":"A Franco","year":"2021","unstructured":"Franco, A., et al. (2021). Truncation-driven lateral association of \u03b1-synuclein hinders amyloid clearance by the Hsp70-based disaggregase. International Journal of Molecular Sciences, 22(23), 12983.","journal-title":"International Journal of Molecular Sciences"},{"key":"8948_CR74","doi-asserted-by":"crossref","unstructured":"Gadbois, G. E. (2026). A Degron Decoy System Co-opts Pathological Seeding to Enable Clearance of Multimeric \u03b1-Synuclein. bioRxiv.","DOI":"10.64898\/2026.02.23.706428"},{"issue":"2","key":"8948_CR68","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/brainsci16020154","volume":"16","author":"P Goyal","year":"2026","unstructured":"Goyal, P., et al. (2026). Neuroimmune Interactions in Neurodegeneration: The Role of Microglia in Alzheimer\u2019s and Parkinson\u2019s Disease Pathogenesis. Brain Sciences, 16(2), 154.","journal-title":"Brain Sciences"},{"key":"8948_CR23","doi-asserted-by":"crossref","unstructured":"Gu, M., et al. (2026). Two lysosomal genes ATP13A2 and GBA1 interact to drive neurodegeneration. Molecular Neurodegeneration.","DOI":"10.1186\/s13024-025-00923-z"},{"issue":"22","key":"8948_CR34","doi-asserted-by":"publisher","first-page":"23622","DOI":"10.1074\/jbc.M313784200","volume":"279","author":"M Hashimoto","year":"2004","unstructured":"Hashimoto, M., et al. (2004). \u03b2-Synuclein Regulates Akt Activity in Neuronal Cells: A POSSIBLE MECHANISM FOR NEUROPROTECTION IN PARKINSON\u2032S DISEASE*. Journal of Biological Chemistry, 279(22), 23622\u201323629.","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"8948_CR29","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1002\/med.22047","volume":"44","author":"Y He","year":"2024","unstructured":"He, Y., et al. (2024). Targeting lysosomal quality control as a therapeutic strategy against aging and diseases. Medicinal Research Reviews, 44(6), 2472\u20132509.","journal-title":"Medicinal Research Reviews"},{"key":"8948_CR60","doi-asserted-by":"publisher","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","volume":"709","author":"MX Henderson","year":"2019","unstructured":"Henderson, M. X., Trojanowski, J. Q., & Lee, V. M. Y. (2019). \u03b1-Synuclein pathology in Parkinson\u2019s disease and related \u03b1-synucleinopathies. Neuroscience letters, 709, 134316.","journal-title":"Neuroscience letters"},{"issue":"1","key":"8948_CR56","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich, M. T., et al. (2023). Mitochondrial dysfunction in Parkinson\u2019s disease \u2013 a key disease hallmark with therapeutic potential. Molecular Neurodegeneration, 18(1), 83.","journal-title":"Molecular Neurodegeneration"},{"issue":"9","key":"8948_CR85","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00702-022-02511-7","volume":"129","author":"G H\u00f6glinger","year":"2022","unstructured":"H\u00f6glinger, G., et al. (2022). GBA-associated PD: chances and obstacles for targeted treatment strategies. Journal of Neural Transmission, 129(9), 1219\u20131233.","journal-title":"Journal of Neural Transmission"},{"issue":"1","key":"8948_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/antiox15010073","volume":"15","author":"Y Hu","year":"2026","unstructured":"Hu, Y., et al. (2026). Oxidative Stress and Lysosomal Dysfunction in Neurodegenerative Diseases: Underlying Mechanisms and Nanotherapeutic Targeting Strategies. Antioxidants, 15(1), 73.","journal-title":"Antioxidants"},{"issue":"1","key":"8948_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/mmr.2024.13378","volume":"31","author":"J Huang","year":"2024","unstructured":"Huang, J., & Wang, J. (2024). Selective protein degradation through chaperone\u2013mediated autophagy: Implications for cellular homeostasis and disease. Molecular Medicine Reports, 31(1), 13.","journal-title":"Molecular Medicine Reports"},{"issue":"11","key":"8948_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/1873-3468.14361","volume":"596","author":"S Huang","year":"2022","unstructured":"Huang, S., et al. (2022). \u03b1-Synuclein phase separation and amyloid aggregation are modulated by C\u2010terminal truncations. FEBS letters, 596(11), 1388\u20131400.","journal-title":"FEBS letters"},{"key":"8948_CR86","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/bs.apha.2024.10.015","volume":"102","author":"M Huang","year":"2025","unstructured":"Huang, M., et al. (2025). Neutral sphingomyelinase 2: A promising drug target for CNS disease. Advances In Pharmacology, 102, 65\u2013101.","journal-title":"Advances In Pharmacology"},{"issue":"1","key":"8948_CR122","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41531-026-01483-9","volume":"12","author":"RM Hughes","year":"2026","unstructured":"Hughes, R. M., et al. (2026). Considerations on combination therapies for disease modification in Parkinson\u2019s. npj Parkinson\u2019s Disease, 12(1), 173.","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"7","key":"8948_CR28","doi-asserted-by":"publisher","first-page":"e70503","DOI":"10.1111\/cns.70503","volume":"31","author":"MS Hussain","year":"2025","unstructured":"Hussain, M. S., et al. (2025). Autophagy and Cellular Senescence in Alzheimer\u2019s Disease: Key Drivers of Neurodegeneration. CNS Neuroscience & Therapeutics, 31(7), e70503.","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"5","key":"8948_CR116","doi-asserted-by":"publisher","first-page":"e209137","DOI":"10.1212\/WNL.0000000000209137","volume":"102","author":"RM Hutchison","year":"2024","unstructured":"Hutchison, R. M., et al. (2024). Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Neurology, 102(5), e209137.","journal-title":"Neurology"},{"key":"8948_CR39","doi-asserted-by":"crossref","unstructured":"Br\u00e1s, I. C., & Outeiro, T. F. (2021). Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies. Cells, 10(2), 229 .","DOI":"10.3390\/cells10020375"},{"key":"8948_CR6","doi-asserted-by":"publisher","first-page":"1003997","DOI":"10.3389\/fnins.2022.1003997","volume":"16","author":"A Iyer","year":"2022","unstructured":"Iyer, A., Sidhu, A., & Subramaniam, V. (2022). How important is the N-terminal acetylation of alpha-synuclein for its function and aggregation into amyloids? Frontiers in Neuroscience, 16, 1003997.","journal-title":"Frontiers in Neuroscience"},{"key":"8948_CR54","doi-asserted-by":"crossref","unstructured":"Joshi, N., Raveendran, A., & Nagotu, S. (2020). Chaperones and Proteostasis: Role in Parkinson\u2019s Disease. Diseases, 8(2), 23 .","DOI":"10.3390\/diseases8020024"},{"issue":"12","key":"8948_CR66","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41582-024-01023-0","volume":"20","author":"LV Kalia","year":"2024","unstructured":"Kalia, L. V., et al. (2024). Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis. Nature Reviews Neurology, 20(12), 724\u2013737.","journal-title":"Nature Reviews Neurology"},{"key":"8948_CR94","doi-asserted-by":"crossref","unstructured":"Kaushik, S. (2025). Chaperone-Mediated Autophagy in Health and Disease, In: Autophagy-From Molecular Mechanisms to Flux Control in Health and Disease (pp. 283\u2013309). Springer.","DOI":"10.1007\/978-3-031-88121-3_11"},{"issue":"1","key":"8948_CR121","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41531-024-00738-7","volume":"10","author":"Y Kuang","year":"2024","unstructured":"Kuang, Y., et al. (2024). A skin-specific \u03b1-Synuclein seeding amplification assay for diagnosing Parkinson\u2019s disease. npj Parkinson\u2019s Disease, 10(1), 129.","journal-title":"npj Parkinson\u2019s Disease"},{"key":"8948_CR80","doi-asserted-by":"publisher","first-page":"118110","DOI":"10.1016\/j.ejmech.2025.118110","volume":"300","author":"G Kumar","year":"2025","unstructured":"Kumar, G., et al. (2025). Contemporary trends in targeted protein degradation for neurodegenerative diseases. European Journal of Medicinal Chemistry, 300, 118110.","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"1","key":"8948_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-025-00797-1","volume":"20","author":"G Kuo","year":"2025","unstructured":"Kuo, G., et al. (2025). Emerging targets of \u03b1-synuclein spreading in \u03b1-synucleinopathies: a review of mechanistic pathways and interventions. Molecular Neurodegeneration, 20(1), 10.","journal-title":"Molecular Neurodegeneration"},{"key":"8948_CR4","doi-asserted-by":"crossref","unstructured":"Leri, M. (2026). Differential roles of proteasome and autophagy in \u03b1-synuclein and E46K oligomer clearance: insight into the modulatory effects of the dopamine metabolite DOPAC. International Journal of Biological Macromolecules, 341(1), 150224.","DOI":"10.1016\/j.ijbiomac.2026.150224"},{"issue":"1","key":"8948_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4103\/NRR.NRR-D-24-00764","volume":"21","author":"X Lian","year":"2026","unstructured":"Lian, X., et al. (2026). Targeting the glymphatic system to promote \u03b1-synuclein clearance: a novel therapeutic strategy for Parkinson\u2019s disease. Neural Regeneration Research, 21(1), 233\u2013247.","journal-title":"Neural Regeneration Research"},{"issue":"22","key":"8948_CR77","doi-asserted-by":"publisher","first-page":"12114","DOI":"10.3390\/ijms252212114","volume":"25","author":"SC Lin","year":"2024","unstructured":"Lin, S. C., et al. (2024). Protective Effects of Ambroxol on A\u03b2 and \u03b1-Synuclein-Induced Neurotoxicity Through Glucocerebrosidase Activation in HT-22 Hippocampal Neuronal Cells. International Journal of Molecular Sciences, 25(22), 12114.","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"8948_CR120","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41531-022-00357-0","volume":"8","author":"P Magalh\u00e3es","year":"2022","unstructured":"Magalh\u00e3es, P., & Lashuel, H. A. (2022). Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson\u2019s disease and other synucleinopathies. npj Parkinson\u2019s Disease, 8(1), 93.","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"2","key":"8948_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.stemcr.2024.01.001","volume":"19","author":"A Mamais","year":"2024","unstructured":"Mamais, A., et al. (2024). The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons. Stem Cell Reports, 19(2), 163\u2013173.","journal-title":"Stem Cell Reports"},{"key":"8948_CR40","doi-asserted-by":"crossref","unstructured":"Manolopoulos, A., Yao, P. J., & Kapogiannis, D. (2025). Extracellular vesicles: translational research and applications in neurology. Nature Reviews Neurology, 21(5), 1\u201318.","DOI":"10.1038\/s41582-025-01080-z"},{"key":"8948_CR72","doi-asserted-by":"publisher","first-page":"852003","DOI":"10.3389\/fneur.2022.852003","volume":"13","author":"S Menon","year":"2022","unstructured":"Menon, S., et al. (2022). Alpha-Synuclein Targeting Therapeutics for Parkinson\u2019s Disease and Related Synucleinopathies. Frontiers In Neurology, 13, 852003.","journal-title":"Frontiers In Neurology"},{"key":"8948_CR18","doi-asserted-by":"crossref","unstructured":"Milmile, M., et al. (2026). Dysfunctional Ubiquitin-Proteasome System and Consequences: Disease Mechanism, In: Ubiquitin Proteasome System in CNS Neurodegenerative Diseases (pp. 17\u201338). Springer.","DOI":"10.1007\/978-981-95-6099-8_2"},{"key":"8948_CR9","unstructured":"Moon, S. P. (2023). Understanding the Roles of Posttranslational Modifications in Aggregation Using Synthetic Proteins. University of Southern California."},{"issue":"10423","key":"8948_CR42","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris, H. R., et al. (2024). The pathogenesis of Parkinson\u2019s disease. The Lancet, 403(10423), 293\u2013304.","journal-title":"The Lancet"},{"issue":"13","key":"8948_CR112","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.3390\/ijms25137183","volume":"25","author":"M Muleiro Alvarez","year":"2024","unstructured":"Muleiro Alvarez, M., et al. (2024). A comprehensive approach to Parkinson\u2019s disease: addressing its molecular, clinical, and therapeutic aspects. International journal of molecular sciences, 25(13), 7183.","journal-title":"International journal of molecular sciences"},{"key":"8948_CR69","doi-asserted-by":"publisher","first-page":"1755292","DOI":"10.3389\/fnmol.2026.1755292","volume":"19","author":"DT Murphy","year":"2026","unstructured":"Murphy, D. T., & Lo, C. H. (2026). Lysosome trafficking across intracellular and intercellular networks in the brain. Frontiers in Molecular Neuroscience, 19, 1755292.","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"4","key":"8948_CR124","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.3233\/JPD-212555","volume":"12","author":"M Negrini","year":"2022","unstructured":"Negrini, M., et al. (2022). Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits. J Parkinsons Dis, 12(4), 1133\u20131153.","journal-title":"J Parkinsons Dis"},{"key":"8948_CR61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.parkreldis.2021.07.028","volume":"90","author":"L Niemann","year":"2021","unstructured":"Niemann, L., et al. (2021). Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson\u2019s disease (MARK-PD). Parkinsonism & related disorders, 90, 44\u201348.","journal-title":"Parkinsonism & related disorders"},{"issue":"1","key":"8948_CR24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00401-024-02799-7","volume":"148","author":"RA Nixon","year":"2024","unstructured":"Nixon, R. A. (2024). Autophagy\u2013lysosomal-associated neuronal death in neurodegenerative disease. Acta Neuropathologica, 148(1), 42.","journal-title":"Acta Neuropathologica"},{"issue":"11","key":"8948_CR27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41580-024-00757-5","volume":"25","author":"RA Nixon","year":"2024","unstructured":"Nixon, R. A., & Rubinsztein, D. C. (2024). Mechanisms of autophagy\u2013lysosome dysfunction in neurodegenerative diseases. Nature Reviews Molecular Cell Biology, 25(11), 926\u2013946.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"21","key":"8948_CR109","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.3390\/cells11213445","volume":"11","author":"FJ Padilla-God\u00ednez","year":"2022","unstructured":"Padilla-God\u00ednez, F. J., Ruiz-Ortega, L. I., & Guerra-Crespo, M. (2022). Nanomedicine in the face of Parkinson\u2019s disease: from drug delivery systems to nanozymes. Cells, 11(21), 3445.","journal-title":"Cells"},{"issue":"1","key":"8948_CR119","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41531-024-00845-5","volume":"10","author":"G Pagano","year":"2024","unstructured":"Pagano, G., et al. (2024). Biologically defined neuronal synuclein disease as a tool to advance drug development. npj Parkinson\u2019s Disease, 10(1), 235.","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"4","key":"8948_CR117","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano, G., et al. (2024). Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nature Medicine, 30(4), 1096\u20131103.","journal-title":"Nature Medicine"},{"issue":"1","key":"8948_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neuron.2024.09.015","volume":"113","author":"JE Palmer","year":"2025","unstructured":"Palmer, J. E., et al. (2025). Autophagy, aging, and age-related neurodegeneration. Neuron, 113(1), 29\u201348.","journal-title":"Neuron"},{"issue":"1","key":"8948_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41582-024-01043-w","volume":"21","author":"H Park","year":"2025","unstructured":"Park, H., et al. (2025). \u03b1-Synuclein pathology as a target in neurodegenerative diseases. Nature Reviews Neurology, 21(1), 32\u201347.","journal-title":"Nature Reviews Neurology"},{"issue":"1","key":"8948_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/biophysica6010012","volume":"6","author":"I Passi","year":"2026","unstructured":"Passi, I., et al. (2026). Autophagy\u2013Proteasome Crosstalk in Neurodegenerative Diseases: Cellular Proteostasis, Neural Interactions, and Therapeutic Implications. Biophysica, 6(1), 12.","journal-title":"Biophysica"},{"key":"8948_CR13","doi-asserted-by":"publisher","unstructured":"Patel, R. (2026). Role of TFEB in parkinson\u2019s disease: pathophysiological insights and therapeutic approaches. Neurophysiology, 56, 169\u2013186. https:\/\/doi.org\/10.1007\/s11062-026-09996-y","DOI":"10.1007\/s11062-026-09996-y"},{"key":"8948_CR47","doi-asserted-by":"publisher","first-page":"104525","DOI":"10.1016\/j.nbd.2019.104525","volume":"130","author":"JR Patterson","year":"2019","unstructured":"Patterson, J. R., et al. (2019). Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal \u03b1-synuclein preformed fibrils. Neurobiology Of Diseases, 130, 104525.","journal-title":"Neurobiology Of Diseases"},{"key":"8948_CR101","doi-asserted-by":"publisher","unstructured":"Pandian, S. R. K. (2022). Liposomes: An emerging carrier for targeting Alzheimer\u2019s and Parkinson\u2019s diseases. Heliyon, 8(6), e09575. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09575","DOI":"10.1016\/j.heliyon.2022.e09575"},{"issue":"1","key":"8948_CR48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13041-023-01059-1","volume":"16","author":"D P\u00e9rez-Acu\u00f1a","year":"2023","unstructured":"P\u00e9rez-Acu\u00f1a, D., et al. (2023). \u03b1-Synuclein propagation leads to synaptic abnormalities in the cortex through microglial synapse phagocytosis. Molecular Brain, 16(1), 72.","journal-title":"Molecular Brain"},{"key":"8948_CR83","doi-asserted-by":"publisher","unstructured":"Pradas, E., & Martinez-Vicente, M. (2023). The Consequences of GBA Deficiency in the Autophagy-Lysosome System in Parkinson\u2019s Disease Associated with GBA. Cells, 12(1) , 191. https:\/\/doi.org\/10.3390\/cells12010191","DOI":"10.3390\/cells12010191"},{"issue":"1","key":"8948_CR49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-023-00618-6","volume":"10","author":"NC Prymaczok","year":"2024","unstructured":"Prymaczok, N. C., et al. (2024). Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson\u2019s disease. npj Parkinson\u2019s Disease, 10(1), 10.","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"5","key":"8948_CR35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jnc.15134","volume":"156","author":"A Raina","year":"2021","unstructured":"Raina, A., et al. (2021). Dopamine promotes the neurodegenerative potential of \u03b2-synuclein. Journal Of Neurochemistry, 156(5), 674\u2013691.","journal-title":"Journal Of Neurochemistry"},{"issue":"1","key":"8948_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/ijms22010440","volume":"22","author":"S Rastogi","year":"2021","unstructured":"Rastogi, S., et al. (2021). The evolving landscape of exosomes in neurodegenerative diseases: exosomes characteristics and a promising role in early diagnosis. International Journal of Molecular Sciences, 22(1), 440.","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"8948_CR59","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1096\/fj.03-0338rev","volume":"18","author":"A Recchia","year":"2004","unstructured":"Recchia, A., et al. (2004). \u03b1-Synuclein and Parkinson\u2019s disease. The FASEB Journal, 18(6), 617\u2013626.","journal-title":"The FASEB Journal"},{"issue":"1","key":"8948_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.chembiol.2025.12.007","volume":"33","author":"M Renna","year":"2026","unstructured":"Renna, M., et al. (2026). The interplay between autophagy and unconventional secretion in neurodegeneration. Cell Chemical Biology, 33(1), 10\u201332.","journal-title":"Cell Chemical Biology"},{"issue":"7","key":"8948_CR62","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00702-019-02025-9","volume":"126","author":"P Riederer","year":"2019","unstructured":"Riederer, P., et al. (2019). \u03b1-Synuclein in Parkinson\u2019s disease: causal or bystander? Journal of neural transmission, 126(7), 815\u2013840.","journal-title":"Journal of neural transmission"},{"key":"8948_CR17","doi-asserted-by":"publisher","unstructured":"Rivault, A., Dussart-Gautheret, J., Benhida, R., Martin, A. R., Auberger, P., Jacquel, A., & Robert, G. (2026). Molecular engineering of lysosome-based degraders unveils a rapidly expanding therapeutic strategy. Autophagy, 22(5), 881\u2013903. https:\/\/doi.org\/10.1080\/15548627.2026.2618626","DOI":"10.1080\/15548627.2026.2618626"},{"issue":"8","key":"8948_CR99","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1093\/brain\/awae070","volume":"147","author":"JC Rubilar","year":"2024","unstructured":"Rubilar, J. C., Outeiro, T. F., & Klein, A. D. (2024). The lysosomal \u03b2-glucocerebrosidase strikes mitochondria: Implications for Parkinson\u2019s therapeutics. Brain, 147(8), 2610\u20132620.","journal-title":"Brain"},{"key":"8948_CR25","unstructured":"Rubinsztein, D., & Nixon, R. (2024). Mechanisms of Autophagy\u2013Lysosome Dysfunction in Neurodegenerative Diseases."},{"issue":"4","key":"8948_CR114","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s13311-020-00920-8","volume":"17","author":"SA Schneider","year":"2020","unstructured":"Schneider, S. A., Hizli, B., & Alcalay, R. N. (2020). Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism. Neurotherapeutics, 17(4), 1378\u20131392.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"8948_CR87","doi-asserted-by":"publisher","first-page":"e00510","DOI":"10.1016\/j.neurot.2024.e00510","volume":"22","author":"D Sehlin","year":"2025","unstructured":"Sehlin, D., et al. (2025). A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology. Neurotherapeutics, 22(2), e00510.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"8948_CR118","doi-asserted-by":"publisher","first-page":"fcaf304","DOI":"10.1093\/braincomms\/fcaf304","volume":"7","author":"C Shering","year":"2025","unstructured":"Shering, C., et al. (2025). Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free \u03b1-synuclein lowered by >\u200950. Brain Commun, 7(5), fcaf304.","journal-title":"Brain Commun"},{"key":"8948_CR7","unstructured":"Shimogawa, M. (2025). Modifications in \u03b1-synuclein: insights into aggregation, structure, and function. University of Pennsylvania. SITE-Specific Incorporation of Post-TranslationaL."},{"issue":"3","key":"8948_CR113","doi-asserted-by":"publisher","first-page":"20220079","DOI":"10.1098\/rsfs.2022.0079","volume":"13","author":"JM Shine","year":"2023","unstructured":"Shine, J. M. (2023). Neuromodulatory control of complex adaptive dynamics in the brain. Interface focus, 13(3), 20220079.","journal-title":"Interface focus"},{"issue":"8","key":"8948_CR115","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2025.1687","volume":"82","author":"CRA Silveira","year":"2025","unstructured":"Silveira, C. R. A., et al. (2025). Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurology, 82(8), 797\u2013807.","journal-title":"JAMA Neurology"},{"key":"8948_CR84","doi-asserted-by":"publisher","unstructured":"Smith, L., & Schapira, A. H. V. (2022). GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 11(8), 1261. https:\/\/doi.org\/10.3390\/cells11081261","DOI":"10.3390\/cells11081261"},{"issue":"8","key":"8948_CR64","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith, L., & Schapira, A. H. (2022). GBA variants and Parkinson disease: mechanisms and treatments. Cells, 11(8), 1261.","journal-title":"Cells"},{"issue":"1","key":"8948_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-019-01977-2","volume":"138","author":"ZA Sorrentino","year":"2019","unstructured":"Sorrentino, Z. A., Giasson, B. I., & Chakrabarty, P. (2019). \u03b1-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta Neuropathologica, 138(1), 1\u201321.","journal-title":"Acta Neuropathologica"},{"issue":"10","key":"8948_CR89","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/mt.2014.129","volume":"22","author":"B Spencer","year":"2014","unstructured":"Spencer, B., et al. (2014). ESCRT-mediated uptake and degradation of brain-targeted \u03b1-synuclein single chain antibody attenuates neuronal degeneration in vivo. Molecular Therapy, 22(10), 1753\u20131767.","journal-title":"Molecular Therapy"},{"issue":"12","key":"8948_CR65","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi, F., et al. (2024). Parkinson disease therapy: current strategies and future research priorities. Nature Reviews Neurology, 20(12), 695\u2013707.","journal-title":"Nature Reviews Neurology"},{"issue":"1","key":"8948_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00441-017-2704-y","volume":"373","author":"I Stojkovska","year":"2018","unstructured":"Stojkovska, I., Krainc, D., & Mazzulli, J. R. (2018). Molecular mechanisms of \u03b1-synuclein and GBA1 in Parkinson\u2019s disease. Cell and tissue research, 373(1), 51\u201360.","journal-title":"Cell and tissue research"},{"key":"8948_CR36","doi-asserted-by":"crossref","unstructured":"Sulek, A. (2024). Secretome\u2013the role of extracellular vesicles in the pathogenesis and therapy of neurodegenerative diseases. Advances in Psychiatry and Neurology\/Post\u0119py Psychiatrii i Neurologii, 33 (3) , 147\u2013162.","DOI":"10.5114\/ppn.2024.144686"},{"issue":"1","key":"8948_CR91","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1038\/s41467-025-59249-5","volume":"16","author":"\u00c9M Szeg\u0151","year":"2025","unstructured":"Szeg\u0151, \u00c9. M., et al. (2025). Intermittent fasting reduces alpha-synuclein pathology and functional decline in a mouse model of Parkinson\u2019s disease. Nature Communications, 16(1), 4470.","journal-title":"Nature Communications"},{"issue":"5","key":"8948_CR76","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.ymthe.2025.03.030","volume":"33","author":"S Szunyogh","year":"2025","unstructured":"Szunyogh, S., Carroll, E., & Wade-Martins, R. (2025). Recent developments in gene therapy for Parkinson\u2019s disease. Molecular Therapy, 33(5), 2052\u20132064.","journal-title":"Molecular Therapy"},{"issue":"15","key":"8948_CR111","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/cells14151161","volume":"14","author":"M Tanaka","year":"2025","unstructured":"Tanaka, M. (2025). Parkinson\u2019s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation. Cells, 14(15), 1161.","journal-title":"Cells"},{"key":"8948_CR81","doi-asserted-by":"crossref","unstructured":"Thomas, B. A. I. (2023). Central Nervous System Targeted Protein Degraders. Biomolecules, 13(8) , 1164.","DOI":"10.3390\/biom13081164"},{"issue":"17","key":"8948_CR107","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1039\/D3NA00180F","volume":"5","author":"A Tomitaka","year":"2023","unstructured":"Tomitaka, A., et al. (2023). Machine learning assisted-nanomedicine using magnetic nanoparticles for central nervous system diseases. Nanoscale Advances, 5(17), 4354\u20134367.","journal-title":"Nanoscale Advances"},{"issue":"11","key":"8948_CR8","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cells11111732","volume":"11","author":"M Vidovi\u0107","year":"2022","unstructured":"Vidovi\u0107, M., & Rikalovic, M. G. (2022). Alpha-synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches. Cells, 11(11), 1732.","journal-title":"Cells"},{"issue":"3","key":"8948_CR11","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/ijms27031164","volume":"27","author":"M Wang","year":"2026","unstructured":"Wang, M., & Wu, M. (2026). Critical Roles and Molecular Mechanisms of Chaperone-Mediated Autophagy in Infections. International Journal of Molecular Sciences, 27(3), 1164.","journal-title":"International Journal of Molecular Sciences"},{"key":"8948_CR73","doi-asserted-by":"publisher","first-page":"102811","DOI":"10.1016\/j.sbi.2024.102811","volume":"86","author":"B Wang","year":"2024","unstructured":"Wang, B., Cao, S., & Zheng, N. (2024). Emerging strategies for prospective discovery of molecular glue degraders. Current Opinion in Structural Biology, 86, 102811.","journal-title":"Current Opinion in Structural Biology"},{"issue":"1","key":"8948_CR16","doi-asserted-by":"publisher","first-page":"e01344","DOI":"10.1128\/jvi.01344-25","volume":"100","author":"Y Wang","year":"2026","unstructured":"Wang, Y., et al. (2026). GRP75 blocks hepatitis E virus infection by targeting HEV-ORF2 for degradation through chaperone-mediated autophagy and promoting IRF3 activation. Journal of Virology, 100(1), e01344\u2013e01325.","journal-title":"Journal of Virology"},{"key":"8948_CR22","doi-asserted-by":"crossref","unstructured":"Wen, S. (2026). Irgm1 Promotes Microglial Clearance of \u03b1-Synuclein via the TFEB-Dependent Autophagy-Lysosome Pathway in Parkinson\u2019s Disease.","DOI":"10.21203\/rs.3.rs-9004768\/v1"},{"issue":"3","key":"8948_CR100","doi-asserted-by":"publisher","first-page":"eado4927","DOI":"10.1126\/sciadv.ado4927","volume":"11","author":"J Wu","year":"2025","unstructured":"Wu, J., et al. (2025). A nanoparticle-based wireless deep brain stimulation system that reverses Parkinson\u2019s disease. Science Advances, 11(3), eado4927.","journal-title":"Science Advances"},{"issue":"4","key":"8948_CR93","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41401-024-01416-3","volume":"46","author":"J Wu","year":"2025","unstructured":"Wu, J., et al. (2025). Targeting chaperone-mediated autophagy in neurodegenerative diseases: mechanisms and therapeutic potential. Acta pharmacologica Sinica, 46(4), 816\u2013828.","journal-title":"Acta pharmacologica Sinica"},{"issue":"7","key":"8948_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1042\/EBC20210028","volume":"65","author":"Y Xia","year":"2021","unstructured":"Xia, Y., Lloyd, G. M., & Giasson, B. I. (2021). Targeted proteolytic products of \u03c4 and \u03b1-synuclein in neurodegeneration. Essays in Biochemistry, 65(7), 905\u2013912.","journal-title":"Essays in Biochemistry"},{"issue":"13","key":"8948_CR33","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1021\/acschemneuro.4c00263","volume":"15","author":"M Xian","year":"2024","unstructured":"Xian, M., et al. (2024). \u03b2-Synuclein Intermediates \u03b1-Synuclein Neurotoxicity in Parkinson\u2019s Disease. Acs Chemical Neuroscience, 15(13), 2445\u20132453.","journal-title":"Acs Chemical Neuroscience"},{"issue":"4","key":"8948_CR98","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3892\/br.2025.1952","volume":"22","author":"M Yang","year":"2025","unstructured":"Yang, M., et al. (2025). ZKSCAN3 affects the autophagy\u2013lysosome pathway through TFEB in Parkinson\u2019s disease. Biomedical Reports, 22(4), 74.","journal-title":"Biomedical Reports"},{"issue":"8","key":"8948_CR104","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.3390\/ijms26083915","volume":"26","author":"YP Yang","year":"2025","unstructured":"Yang, Y. P., Nicol, C. J., & Chiang, M. C. (2025). A Review of the Neuroprotective Properties of Exosomes Derived from Stem Cells and Exosome-Coated Nanoparticles for Treating Neurodegenerative Diseases and Stroke. International Journal of Molecular Sciences, 26(8), 3915.","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"8948_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5483\/BMBRep.2022.55.7.073","volume":"55","author":"H Yoo","year":"2022","unstructured":"Yoo, H., et al. (2022). Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson\u2019s disease. BMB reports, 55(7), 323.","journal-title":"BMB reports"},{"issue":"2","key":"8948_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/antiox15020187","volume":"15","author":"Y Yordanov","year":"2026","unstructured":"Yordanov, Y., et al. (2026). Sources of Oxidative Stress in Parkinson\u2019s Disease: Pathways and Therapeutic Implications. Antioxidants, 15(2), 187.","journal-title":"Antioxidants"},{"issue":"1","key":"8948_CR78","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang, X., et al. (2024). Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson\u2019s disease. Transl Neurodegener, 13(1), 48.","journal-title":"Transl Neurodegener"},{"issue":"1","key":"8948_CR75","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40035-024-00437-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang, X., et al. (2024). Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson\u2019s disease. Translational Neurodegeneration, 13(1), 48.","journal-title":"Translational Neurodegeneration"}],"container-title":["NeuroMolecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-026-08948-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12017-026-08948-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12017-026-08948-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:03:53Z","timestamp":1788246233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12017-026-08948-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8948"],"URL":"https:\/\/doi.org\/10.1007\/s12017-026-08948-3","relation":{},"ISSN":["1559-1174"],"issn-type":[{"value":"1559-1174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"51"}}